Moleculin Biotech (MBRX) Stock Price, News & Analysis

Company Overview

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression.

Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma. The company has also developed investigational compounds including WP1066, an immunotherapy candidate designed to inhibit STAT3 and related signaling pathways, and WP1122, which is intended to interfere with cancer-cell glucose metabolism. These programs remain in clinical or preclinical development and are not approved for general commercial use.

Headquartered in Houston, Texas, Moleculin conducts research and clinical-development activities in the United States and has pursued clinical programs in Europe. The company is led by Walter Klemp, who serves as chairman and chief executive officer. Moleculin Biotech trades on the Nasdaq Capital Market under the symbol MBRX.

Key Stats

• Today's Range: $7.90 to $9.00
• 50-Day Range: $5.30 to $16.60
• 52-Week Range: $3.23 to $315.00
• Volume: 31,716 shs
• Average Volume: 45,218 shs
• Market Capitalization: $8.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Hold

Moleculin Biotech Stock Analysis - MarketRank™

Moleculin Biotech scored higher than 74% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Moleculin Biotech has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Moleculin Biotech has a consensus price target of $60.00, representing about 659.5% upside from its current price of $7.90.

Amount of Analyst Coverage

Moleculin Biotech has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Moleculin Biotech are expected to grow in the coming year, from ($47.40) to ($23.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Moleculin Biotech is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Moleculin Biotech is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Moleculin Biotech has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.00% of the float of Moleculin Biotech has been sold short.

Short Interest Ratio / Days to Cover

Moleculin Biotech has a short interest ratio ("days to cover") of 0.36, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Moleculin Biotech has recently decreased by 38.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Moleculin Biotech does not currently pay a dividend.

Dividend Growth

Moleculin Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.83

News Sentiment

Moleculin Biotech has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Moleculin Biotech this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for MBRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Moleculin Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Moleculin Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.04% of the stock of Moleculin Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

15.52% of the stock of Moleculin Biotech is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/31/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:MBRX
• CIK: 1659617
• Web: www.moleculin.com
• Phone: (713) 300-5160
• Fax: N/A
• Employees: 17
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Moleculin Biotech: $60.00
• High Price Target: $60.00
• Low Price Target: $60.00
• Potential Upside/Downside: +659.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -143.51%
• Return on Assets: -24.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.94
• Quick Ratio: 0.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $93.81 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 1,030,000
• Free Float: 842,000
• Market Cap: $8.14 million
• Optionable: Not Optionable
• Beta: 2.00